GAVI announces $1.2bn African vaccine manufacturing fund
Alongside its direct funding commitment to Nigeria, GAVI announced the rollout of a $1.2 billion African Vaccine Manufacturing Accelerator to boost vaccine production in Nigeria.
Alongside its direct funding commitment to Nigeria, GAVI announced the rollout of a $1.2 billion African Vaccine Manufacturing Accelerator (AVMA). The initiative aims to provide commercial incentives and technical support to boost localized vaccine manufacturing facilities in Nigeria and across the African continent.
The AVMA is a significant step towards African vaccine self-sufficiency. The COVID-19 pandemic exposed the continent’s reliance on imported vaccines, and the AVMA is designed to address that vulnerability. The initiative will provide funding and technical support to vaccine manufacturers, enabling them to scale up production and meet local demand.
The Nigerian stake is clear. Nigeria is one of the countries that will benefit from the AVMA, with direct funding commitments already made. The initiative could help Nigeria develop a domestic vaccine manufacturing industry, reducing its reliance on imports.
From a Nigerian vantage point, the AVMA is a welcome development. The country has been seeking to build its pharmaceutical manufacturing capacity, and the AVMA provides an opportunity to do so. The challenge is to ensure that the funding is used effectively.
This echoes the 2020s push for vaccine manufacturing in Africa, which has gained momentum since the pandemic. The mechanism then was different, but the result was the same: a recognition that Africa must build its own vaccine manufacturing capacity.
The winners: African vaccine manufacturers, who will receive funding and support; and the African continent, which will gain vaccine self-sufficiency. The losers: the Nigerian government, which must ensure the funding is used effectively; and the Nigerian public, who must wait for the benefits to materialise.
Bottom Line: GAVI has announced a $1.2 billion fund to boost vaccine manufacturing in Africa. Nigeria is a beneficiary. The goal is vaccine self-sufficiency. The question is whether the initiative will succeed or fail.